drugset
drugset / Trial / NCT05220124

A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

NCT05220124 ↗

Phase 4 Unknown 190 enrolled Tianjin Medical University Second Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.

Timeline

Start
2022-01-05
Primary completion
2024-11-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus Unknown 420 mg —

Indications

urinary bladder cancer